RxDoctor Payments DataLook up a doctor →

Joseph Christenbury, MD

Cornea and External Diseases Specialist · Atlanta, GANPI 1679816458

Payments from drug & device makers

$261,526in general payments, 2019–2025

Across 335 payments — averaging $780.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$105K
  • Dompe Farmaceutici S.p.a.$82K
  • Novartis$36K
  • Biotissue Holdings Inc.$14K
  • Glaukos Corporation$11K
  • Dompe US, Inc.$5K
  • plus $8K from 27 others

What the payments were for

  • Consulting fees$12,30040%
  • Speaking & faculty fees$4,83916%
  • Travel & lodging$2,5168%
  • Food & beverage$11,31436%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$354,836
Medicare patients
848
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj16$903,934
RestasisCyclosporine130$115,417
XiidraLifitegrast44$45,522
Cyclosporine63$45,262
MieboPerfluorohexyloctane/Pf27$24,058
TyrvayaVarenicline Tartrate25$23,891
Prednisolone Acetate724$23,847
LumiganBimatoprost31$16,198
CequaCyclosporine16$14,446
MoxifloxacinMoxifloxacin Hcl558$11,716
Fluorometholone125$11,468
CombiganBrimonidine Tartrate/Timolol29$7,787
Brimonidine Tartrate73$6,539
ValacyclovirValacyclovir Hcl131$6,114
Alphagan PBrimonidine Tartrate16$5,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$5,088$903,93416 claims
AbbVieRestasis, Lumigan, Combigan, Alphagan P$618$145,085206 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$300$69,58071 claims
Oyster Point Pharma, Inc.Tyrvaya$455$23,89125 claims
Sun Pharmaceutical Industries Inc.Cequa$587$14,44616 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa$79$9,69035 claims
AlconSimbrinza$1,662$4,35519 claims
Eyevance Pharmaceuticals LLCFlarex$24$1,47712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →